-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Annals of the Rheumatic Diseases, a top journal in the field of rheumatism, published a research article that aims to evaluate the outcome of seasonal flu in patients with inflammatory joint disease (IJD) and disease-modifying anti-rheumatic drugs (DMARD) The absolute and relative risks of COVID-19 , and summarize the results of recent research on the corresponding COVID-19 risks
.
In this cohort study, researchers used the Swedish National Registry to follow up 116989 IJD patients and matched population controls.
The subjects spanned four flu seasons (2015-2019)
.
The researchers quantified the absolute risk of hospitalization and death due to influenza, and compared IJD patients with controls through Cox regression
.
At the beginning of each flu season, researchers identified 71,556 patients with IJD who were actively treated with conventional synthetic DMARDs and biological disease mitigating antirheumatic drugs (bDMARDs)/targeted synthetic disease mitigating antirheumatic drugs (tsDMARDs), and estimated the same outcome The risks of different DMARD groups were compared through Cox regression
Each season, the average risk of hospitalization for IJD patients due to influenza is 0.
25%, and that of the general population is 0.
1%.
The corresponding rough HR is 2.
38 (95% CI 2.
21 to 2.
56), and after adjusting for comorbidities, it drops to 1.
44 (95% CI is 1.
33 to 1.
56)
.
For influenza that is on the death list, the corresponding figures are 0.
It can be seen that, in absolute terms, the number of COVID-19 cases in patients with IJD exceeds the average seasonal flu, but IJD causes the risk of hospitalization and death for the two infections to increase by 50%-100%, which depends to a large extent.
For related comorbidities
.
Overall, treatment with bDMARDs/tsDMARDs does not seem to increase the risk of hospitalization or death associated with seasonal influenza
In absolute terms, the number of COVID-19 cases in patients with IJD exceeds the average seasonal flu, but IJD causes the risk of hospitalization and death for the two infections to increase by 50%-100%, depending on the related mergers.
Original source:
Hannah Bower,et al.
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Leave a message here
